Management of the patient with an acute coronary syndrome using oral anticoagulation
- PMID: 26184420
- PMCID: PMC4547947
- DOI: 10.1007/s12471-015-0727-0
Management of the patient with an acute coronary syndrome using oral anticoagulation
Abstract
A significant number of patients with atrial fibrillation, treated with oral anticoagulants, present with an acute coronary syndrome. Many of these patients have an indication for coronary angiography. The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) and the novel P2Y12 inhibitors has generated new uncertainty about the optimal treatment regimen, whether triple or dual therapy should be given and which is the most beneficial P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel). In this article, we will summarise the practical advice on the management of acute coronary syndrome patients requiring oral anticoagulants following the recent consensus document of the European Society of Cardiology (ESC) Working Group on Thrombosis in association with the European Heart Rhythm Association (EHRA) and ESC guidelines.
Similar articles
-
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).Europace. 2017 Nov 1;19(11):1757-1758. doi: 10.1093/europace/eux240. Europace. 2017. PMID: 29096024 Review.
-
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).Europace. 2019 Feb 1;21(2):192-193. doi: 10.1093/europace/euy174. Europace. 2019. PMID: 30052888 Review.
-
Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).Thromb Haemost. 2017 Dec;117(12):2215-2236. doi: 10.1160/TH-17-10-0709. Epub 2017 Dec 6. Thromb Haemost. 2017. PMID: 29212110
-
Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence.Eur Heart J Cardiovasc Pharmacother. 2021 Jan 16;7(1):68-73. doi: 10.1093/ehjcvp/pvaa047. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 32379867
-
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.Europace. 2015 Oct;17(10):1467-507. doi: 10.1093/europace/euv309. Epub 2015 Aug 31. Europace. 2015. PMID: 26324838
Cited by
-
New guidelines on primary PCI for patients with STEMI: changing insights.Neth Heart J. 2016 Feb;24(2):93-5. doi: 10.1007/s12471-015-0780-8. Neth Heart J. 2016. PMID: 26645713 Free PMC article. No abstract available.
-
Trends in Off-Label Indications of Non-Vitamin K Antagonist Oral Anticoagulants in Acute Coronary Syndrome.Rev Cardiovasc Med. 2023 Jun 25;24(6):180. doi: 10.31083/j.rcm2406180. eCollection 2023 Jun. Rev Cardiovasc Med. 2023. PMID: 39077529 Free PMC article. Review.
-
[Prehospital management of acute coronary syndrome in patients on long-term direct oral anticoagulant treatment].Anaesthesist. 2020 Feb;69(2):108-116. doi: 10.1007/s00101-019-00710-8. Epub 2019 Dec 4. Anaesthesist. 2020. PMID: 31802173 German.
-
Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands.Neth Heart J. 2016 Oct;24(10):589-99. doi: 10.1007/s12471-016-0873-z. Neth Heart J. 2016. PMID: 27573042 Free PMC article.
References
-
- Gao F, Zhou YJ, Wang ZJ. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J Off J Jpn Circ Soc. 2010;74:701–8. - PubMed
-
- Lip GYH, Windecker S, Huber K. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) Eur Heart J. 2014;35:3155–79. doi: 10.1093/eurheartj/ehu298. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources